A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia

Leuk Lymphoma. 2016 Oct;57(10):2441-4. doi: 10.3109/10428194.2016.1138295. Epub 2016 Feb 8.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Azacitidine / adverse effects
  • Azacitidine / therapeutic use*
  • Biomarkers, Pharmacological / metabolism
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Female
  • Humans
  • Leukemia, Myelomonocytic, Chronic / drug therapy*
  • Leukemia, Myelomonocytic, Chronic / genetics
  • Leukemia, Myelomonocytic, Chronic / mortality
  • Leukemia, Myelomonocytic, Chronic / pathology
  • Male
  • Middle Aged
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers, Pharmacological
  • Biomarkers, Tumor
  • Azacitidine